Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electroni...
Gespeichert in:
| Veröffentlicht in: | Revista brasileira de psiquiatria 2012-06, Vol.34 Suppl 1, p.S104-S117 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S117 |
|---|---|
| container_issue | |
| container_start_page | S104 |
| container_title | Revista brasileira de psiquiatria |
| container_volume | 34 Suppl 1 |
| creator | Schier, Alexandre Rafael de Mello Ribeiro, Natalia Pinho de Oliveira Silva, Adriana Cardoso de Oliveira e Hallak, Jaime Eduardo Cecílio Crippa, José Alexandre S Nardi, Antonio E Zuardi, Antonio Waldo |
| description | To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action.
The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints.
Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder.
Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined. |
| doi_str_mv | 10.1016/s1516-4446(12)70057-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1022843393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1022843393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-304147edca1f80cedc4d8354f072671960d2a64f33aa0008e83eb06535416f8e3</originalsourceid><addsrcrecordid>eNo9kN9LwzAQgIMobk7_BKWPClbvkjRJH8fwFwx8UMG3kKWpRLp2Nqm4_97MbcLB3XHf3cFHyDnCDQKK24AFipxzLi6RXkmAQuZwQMaooMx5Qd8PU71HRuQkhE8AKpmSx2REqaRlgsZkOjNtaxa-8l1znZls14YsmOi_TWa7NkQfB9fGNA6ZaVP8JHgdvc2qfvg4JUe1aYI72-UJebu_e5095vPnh6fZdJ5bJjDmDDhy6SprsFZgU8ErxQpeg6RCYimgokbwmjFjAEA5xdwCRJEQFLVybEIut3dXffc1uBD10gfrmsa0rhuCRqBUccZKltBii9q-C6F3tV71fmn6dYL0xp5-2ajRGzUaqf6zpyHtXexeDIulq_639rrYL9LoaVU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1022843393</pqid></control><display><type>article</type><title>Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Schier, Alexandre Rafael de Mello ; Ribeiro, Natalia Pinho de Oliveira ; Silva, Adriana Cardoso de Oliveira e ; Hallak, Jaime Eduardo Cecílio ; Crippa, José Alexandre S ; Nardi, Antonio E ; Zuardi, Antonio Waldo</creator><creatorcontrib>Schier, Alexandre Rafael de Mello ; Ribeiro, Natalia Pinho de Oliveira ; Silva, Adriana Cardoso de Oliveira e ; Hallak, Jaime Eduardo Cecílio ; Crippa, José Alexandre S ; Nardi, Antonio E ; Zuardi, Antonio Waldo</creatorcontrib><description>To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action.
The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints.
Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder.
Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.</description><identifier>ISSN: 1516-4446</identifier><identifier>EISSN: 1809-452X</identifier><identifier>DOI: 10.1016/s1516-4446(12)70057-0</identifier><identifier>PMID: 22729452</identifier><language>eng</language><publisher>Brazil</publisher><subject>Animals ; Anti-Anxiety Agents - therapeutic use ; Anxiety Disorders - drug therapy ; Cannabidiol - therapeutic use ; Cannabis - chemistry ; Disease Models, Animal ; Humans</subject><ispartof>Revista brasileira de psiquiatria, 2012-06, Vol.34 Suppl 1, p.S104-S117</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-304147edca1f80cedc4d8354f072671960d2a64f33aa0008e83eb06535416f8e3</citedby><cites>FETCH-LOGICAL-c361t-304147edca1f80cedc4d8354f072671960d2a64f33aa0008e83eb06535416f8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,865,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22729452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schier, Alexandre Rafael de Mello</creatorcontrib><creatorcontrib>Ribeiro, Natalia Pinho de Oliveira</creatorcontrib><creatorcontrib>Silva, Adriana Cardoso de Oliveira e</creatorcontrib><creatorcontrib>Hallak, Jaime Eduardo Cecílio</creatorcontrib><creatorcontrib>Crippa, José Alexandre S</creatorcontrib><creatorcontrib>Nardi, Antonio E</creatorcontrib><creatorcontrib>Zuardi, Antonio Waldo</creatorcontrib><title>Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug</title><title>Revista brasileira de psiquiatria</title><addtitle>Braz J Psychiatry</addtitle><description>To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action.
The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints.
Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder.
Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.</description><subject>Animals</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Cannabidiol - therapeutic use</subject><subject>Cannabis - chemistry</subject><subject>Disease Models, Animal</subject><subject>Humans</subject><issn>1516-4446</issn><issn>1809-452X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kN9LwzAQgIMobk7_BKWPClbvkjRJH8fwFwx8UMG3kKWpRLp2Nqm4_97MbcLB3XHf3cFHyDnCDQKK24AFipxzLi6RXkmAQuZwQMaooMx5Qd8PU71HRuQkhE8AKpmSx2REqaRlgsZkOjNtaxa-8l1znZls14YsmOi_TWa7NkQfB9fGNA6ZaVP8JHgdvc2qfvg4JUe1aYI72-UJebu_e5095vPnh6fZdJ5bJjDmDDhy6SprsFZgU8ErxQpeg6RCYimgokbwmjFjAEA5xdwCRJEQFLVybEIut3dXffc1uBD10gfrmsa0rhuCRqBUccZKltBii9q-C6F3tV71fmn6dYL0xp5-2ajRGzUaqf6zpyHtXexeDIulq_639rrYL9LoaVU</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Schier, Alexandre Rafael de Mello</creator><creator>Ribeiro, Natalia Pinho de Oliveira</creator><creator>Silva, Adriana Cardoso de Oliveira e</creator><creator>Hallak, Jaime Eduardo Cecílio</creator><creator>Crippa, José Alexandre S</creator><creator>Nardi, Antonio E</creator><creator>Zuardi, Antonio Waldo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug</title><author>Schier, Alexandre Rafael de Mello ; Ribeiro, Natalia Pinho de Oliveira ; Silva, Adriana Cardoso de Oliveira e ; Hallak, Jaime Eduardo Cecílio ; Crippa, José Alexandre S ; Nardi, Antonio E ; Zuardi, Antonio Waldo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-304147edca1f80cedc4d8354f072671960d2a64f33aa0008e83eb06535416f8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Cannabidiol - therapeutic use</topic><topic>Cannabis - chemistry</topic><topic>Disease Models, Animal</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schier, Alexandre Rafael de Mello</creatorcontrib><creatorcontrib>Ribeiro, Natalia Pinho de Oliveira</creatorcontrib><creatorcontrib>Silva, Adriana Cardoso de Oliveira e</creatorcontrib><creatorcontrib>Hallak, Jaime Eduardo Cecílio</creatorcontrib><creatorcontrib>Crippa, José Alexandre S</creatorcontrib><creatorcontrib>Nardi, Antonio E</creatorcontrib><creatorcontrib>Zuardi, Antonio Waldo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista brasileira de psiquiatria</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schier, Alexandre Rafael de Mello</au><au>Ribeiro, Natalia Pinho de Oliveira</au><au>Silva, Adriana Cardoso de Oliveira e</au><au>Hallak, Jaime Eduardo Cecílio</au><au>Crippa, José Alexandre S</au><au>Nardi, Antonio E</au><au>Zuardi, Antonio Waldo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug</atitle><jtitle>Revista brasileira de psiquiatria</jtitle><addtitle>Braz J Psychiatry</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>34 Suppl 1</volume><spage>S104</spage><epage>S117</epage><pages>S104-S117</pages><issn>1516-4446</issn><eissn>1809-452X</eissn><abstract>To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action.
The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references. Experimental animal and human studies were included, with no time restraints.
Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder.
Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.</abstract><cop>Brazil</cop><pmid>22729452</pmid><doi>10.1016/s1516-4446(12)70057-0</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1516-4446 |
| ispartof | Revista brasileira de psiquiatria, 2012-06, Vol.34 Suppl 1, p.S104-S117 |
| issn | 1516-4446 1809-452X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1022843393 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection |
| subjects | Animals Anti-Anxiety Agents - therapeutic use Anxiety Disorders - drug therapy Cannabidiol - therapeutic use Cannabis - chemistry Disease Models, Animal Humans |
| title | Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T09%3A37%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabidiol,%20a%20Cannabis%20sativa%20constituent,%20as%20an%20anxiolytic%20drug&rft.jtitle=Revista%20brasileira%20de%20psiquiatria&rft.au=Schier,%20Alexandre%20Rafael%20de%20Mello&rft.date=2012-06-01&rft.volume=34%20Suppl%201&rft.spage=S104&rft.epage=S117&rft.pages=S104-S117&rft.issn=1516-4446&rft.eissn=1809-452X&rft_id=info:doi/10.1016/s1516-4446(12)70057-0&rft_dat=%3Cproquest_cross%3E1022843393%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1022843393&rft_id=info:pmid/22729452&rfr_iscdi=true |